A股異動 | 邁瑞醫療(300760.SZ)漲近5% 收購全球知名免疫原料供應商HyTest
格隆匯5月17日丨國內醫療器械行業龍頭邁瑞醫療(300760.SZ)漲近5%,報472.61元,股價創近三個月新高,最新總市值5745億元。邁瑞醫療正在加速佈局IVD上游原材料市場。5月16日,邁瑞醫療發佈公吿稱,公司擬通過全資子公司邁瑞全球(香港)有限公司及香港全球的全資子公司Mindray Medical Netherlands B.V.以現金形式收購Hytest Invest Oy及其下屬子公司100%股權。上述交易完成後,邁瑞醫療將間接持有Hytest Invest Oy及其下屬子公司100%的股權。此次收購總價預計約為5.45億歐元。HyTest是全球知名的免疫原材料供應商,主要產品包括單克隆抗體、抗原及血漿製品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.